Generic Vivjoa Availability
Last updated on Dec 12, 2024.
Vivjoa is a brand name of oteseconazole, approved by the FDA in the following formulation(s):
VIVJOA (oteseconazole - capsule;oral)
-
Manufacturer: MYCOVIA PHARMS
Approval date: April 26, 2022
Strength(s): 150MG [RLD]
Has a generic version of Vivjoa been approved?
No. There is currently no therapeutically equivalent version of Vivjoa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vivjoa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Antifungal compounds and processes for making
Patent 10,414,751
Issued: September 17, 2019
Inventor(s): Hoekstra William J. & Wirth David Dale & Ehiwe Tracy & Bonnaud Thierry
Assignee(s): Mycovia Pharmaceuticals, Inc.The present invention relates to polymorphic forms of compound 1 or 1a and processes for preparing compound 1 and 1a polymorphs, which are useful as antifungal agents. In particular, the invention seeks to provide a new methodology for preparing polymorphs of compound 1 and substituted derivatives thereof.
Patent expiration dates:
- March 17, 2036✓✓
- March 17, 2036
-
Patent 11,247,981
Patent expiration dates:
- May 9, 2033✓
- May 9, 2033
-
Metalloenzyme inhibitor compounds
Patent 8,236,962
Issued: August 7, 2012
Inventor(s): Hoekstra William J. & Schotzinger Robert J. & Rafferty Stephen W.
Assignee(s): Viamet Pharmaceuticals, Inc.The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Patent expiration dates:
- April 22, 2031✓✓
- April 22, 2031
-
Metalloenzyme inhibitor compounds
Patent 8,754,227
Issued: June 17, 2014
Inventor(s): Hoekstra William J. & Schotzinger Robert J. & Rafferty Stephen W.
Assignee(s): Viamet Pharmaceuticals, Inc.The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Patent expiration dates:
- April 22, 2031✓
- April 22, 2031
-
Antifungal compounds and processes for making
Patent 9,840,492
Issued: December 12, 2017
Inventor(s): Hoekstra William J. & Wirth David Dale & Ehiwe Tracy & Bonnaud Thierry
Assignee(s): Viamet Pharmaceuticals, Inc.The present invention relates to polymorphic forms of compound 1 or 1a and processes for preparing compound 1 and 1a polymorphs, which are useful as antifungal agents. In particular, the invention seeks to provide a new methodology for preparing polymorphs of compound 1 and substituted derivatives thereof.
Patent expiration dates:
- March 17, 2036✓✓
- March 17, 2036
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 26, 2027 - NEW CHEMICAL ENTITY
- April 26, 2032 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Vivjoa (oteseconazole)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: azole antifungals
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
